Showing 79.4 percent efficacy, single-dose Sputnik Light Covid vaccine authorised in Russia

Published On 2021-05-07 05:30 GMT | Update On 2021-05-07 08:34 GMT

Moscow: Russia has authorised the one-shot Sputnik Light version of its Covid-19 vaccine for use, the Russian Direct Investment Fund (RDIF) said on Thursday, a move that could help vaccine supplies go further in countries with high infection rates.

Developed by Moscow's Gamaleya Institute, the slimmed-down vaccine, which the RDIF said is 79.4% effective against Covid-19 and costs under $10 a dose, has been earmarked for export and could increase the number of people with partial immunity.

One of its main potential uses is as a vaccine that can be shipped to a country in the grip of an acute outbreak which needs to be subdued quickly.

"The single-dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analysed data taken from 28 days after the injection was administered as part of Russia's mass vaccination programme between 5 December 2020 and 15 April 2021," the RDIF said in a statement.

A Phase III clinical trial involving 7,000 people was under way in Russia, the United Arab Emirates, Ghana and other countries, the RDIF said. Interim results are expected later this month.

According to authorities, around 8 million Russians have so far been fully inoculated with the flagship two-dose Sputnik V, named after the Soviet-era satellite that triggered the space race in a nod to the project's geopolitical importance for Moscow.

Russian scientists last month said Sputnik V was 97.6% effective against Covid-19 in a "real-world" assessment based on data from 3.8 million people.

The slower pace of vaccination in Russia compared to other countries with domestically produced vaccines has provoked questions over its export intentions from some European officials. The European Medicines Agency has not yet approved the shot and Austria on Tuesday said it would only buy Sputnik V after EMA approval.

"The single-dose regimen solves the challenge of immunizing large groups in a shorter time, which is especially important during the acute phase of the spread of coronavirus, achieving herd immunity faster," said RDIF head Kirill Dmitriev.

He added that the two-dose Sputnik V vaccine would remain the main source of vaccination in Russia, which has already authorised two other vaccines for use.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment experienced, restarting antiretroviral treatment

2025-08-02 07:00 GMT

Showing 79.4 percent efficacy, single-dose Sputnik Light Covid vaccine authorised in Russia

Similar News

Health Ministry Notifies Cosmetics Rules 2025, Empowers States To Suspend Licences

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray

CDSCO Panel Accepts Phase I Trial Data for Intas' Denosumab Biosimilar

Torrent Pharma: USFDA concludes inspection at Vizag facility with zero observations

Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment experienced, restarting antiretroviral treatment

USFDA issues 4 observations for Jubilant Generics Roorkee facility

Granules India arm gets 1 USFDA observation for Hyderabad facility

CDSCO Panel Clears PURE & CURE's Sickle Cell Trial With Conditions On Sample Size, Sites